908 Devices Inc. (NASDAQ:MASS - Get Rating) CFO Joseph H. Iv Griffith sold 900 shares of the stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $15.01, for a total transaction of $13,509.00. Following the sale, the chief financial officer now owns 91,580 shares in the company, valued at $1,374,615.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of MASS traded up $0.67 during midday trading on Wednesday, reaching $15.77. The stock had a trading volume of 304,357 shares, compared to its average volume of 308,399. The company's fifty day simple moving average is $15.98 and its two-hundred day simple moving average is $18.07. 908 Devices Inc. has a 1-year low of $12.60 and a 1-year high of $41.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 17.78 and a quick ratio of 17.08. The company has a market cap of $495.29 million, a price-to-earnings ratio of -17.92 and a beta of 1.62.
908 Devices (NASDAQ:MASS - Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). 908 Devices had a negative net margin of 56.68% and a negative return on equity of 15.20%. The firm had revenue of $8.31 million for the quarter, compared to analyst estimates of $7.65 million. During the same period last year, the business earned ($0.22) EPS. 908 Devices's revenue for the quarter was up 49.8% compared to the same quarter last year. On average, sell-side analysts forecast that 908 Devices Inc. will post -0.94 earnings per share for the current year.
A number of large investors have recently made changes to their positions in MASS. Quantbot Technologies LP grew its position in 908 Devices by 960.8% during the 1st quarter. Quantbot Technologies LP now owns 6,365 shares of the company's stock worth $120,000 after purchasing an additional 5,765 shares during the last quarter. Goldman Sachs Group Inc. grew its position in 908 Devices by 14.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 64,982 shares of the company's stock worth $1,235,000 after purchasing an additional 8,042 shares during the last quarter. PDT Partners LLC purchased a new position in 908 Devices during the 1st quarter worth $263,000. State Street Corp grew its position in 908 Devices by 13.4% during the 1st quarter. State Street Corp now owns 494,136 shares of the company's stock worth $9,394,000 after purchasing an additional 58,556 shares during the last quarter. Finally, Eversept Partners LP purchased a new position in 908 Devices during the 1st quarter worth $4,128,000. Hedge funds and other institutional investors own 79.24% of the company's stock.
Separately, SVB Leerink reduced their price objective on shares of 908 Devices from $40.00 to $30.00 and set an "outperform" rating on the stock in a report on Tuesday, March 8th.
About 908 Devices (Get Rating)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here